MX2024013496A - Formulaciones de anticuerpos contra el receptor de interleucina 4 (il-4r) - Google Patents

Formulaciones de anticuerpos contra el receptor de interleucina 4 (il-4r)

Info

Publication number
MX2024013496A
MX2024013496A MX2024013496A MX2024013496A MX2024013496A MX 2024013496 A MX2024013496 A MX 2024013496A MX 2024013496 A MX2024013496 A MX 2024013496A MX 2024013496 A MX2024013496 A MX 2024013496A MX 2024013496 A MX2024013496 A MX 2024013496A
Authority
MX
Mexico
Prior art keywords
antibody
interleukin
receptor
formulations
antibody formulations
Prior art date
Application number
MX2024013496A
Other languages
English (en)
Spanish (es)
Inventor
Xiaolin Tang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024013496A publication Critical patent/MX2024013496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MX2024013496A 2022-05-02 2024-10-31 Formulaciones de anticuerpos contra el receptor de interleucina 4 (il-4r) MX2024013496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263337532P 2022-05-02 2022-05-02
PCT/US2023/020660 WO2023215267A1 (en) 2022-05-02 2023-05-02 Anti-interleukin-4 receptor (il-4r) antibody formulations

Publications (1)

Publication Number Publication Date
MX2024013496A true MX2024013496A (es) 2024-12-06

Family

ID=86609834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013496A MX2024013496A (es) 2022-05-02 2024-10-31 Formulaciones de anticuerpos contra el receptor de interleucina 4 (il-4r)

Country Status (12)

Country Link
US (1) US20240024472A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518837A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025516298A (cg-RX-API-DMAC7.html)
KR (1) KR20250004863A (cg-RX-API-DMAC7.html)
CN (1) CN119136787A (cg-RX-API-DMAC7.html)
AU (1) AU2023263975A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250514A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024014835A2 (cg-RX-API-DMAC7.html)
IL (1) IL316264A (cg-RX-API-DMAC7.html)
MX (1) MX2024013496A (cg-RX-API-DMAC7.html)
TW (1) TW202406572A (cg-RX-API-DMAC7.html)
WO (1) WO2023215267A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025017034A1 (en) * 2023-07-17 2025-01-23 Formycon Ag Stable liquid antibody formulation for dupilumab
WO2025116637A1 (ko) * 2023-12-01 2025-06-05 삼성바이오에피스 주식회사 항-IL-4Rα 항체의 안정한 액상 제형
EP4623903A1 (en) * 2024-03-28 2025-10-01 Fresenius Kabi Deutschland GmbH Pharmaceutical composition comprising dupilumab
KR20260105275A (ko) * 2024-12-26 2026-07-06 주식회사 종근당 항-hIL-4Rα 항체를 위한 안정화된 액상 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) * 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
JP5859148B2 (ja) * 2012-03-08 2016-02-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Aβ抗体製剤
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器(二)
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器(二)
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置(五)
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CN110540590B (zh) 2018-05-29 2023-08-18 康诺亚生物医药科技(成都)有限公司 一种自免疫抑制物的开发和应用
MX2021001143A (es) 2018-08-24 2021-04-12 Jiangsu Hengrui Medicine Co Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN111494626B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
SG11202107007VA (en) 2018-12-27 2021-07-29 Akeso Biopharma Inc Antibody against human il-4ra and use thereof
CN111592597B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途

Also Published As

Publication number Publication date
CA3250514A1 (en) 2023-11-09
US20240024472A1 (en) 2024-01-25
AU2023263975A1 (en) 2024-12-12
CN119136787A (zh) 2024-12-13
EP4518837A1 (en) 2025-03-12
WO2023215267A1 (en) 2023-11-09
KR20250004863A (ko) 2025-01-08
TW202406572A (zh) 2024-02-16
CO2024014835A2 (es) 2025-03-06
JP2025516298A (ja) 2025-05-27
IL316264A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
TWI860474B (zh) 冠狀病毒疫苗
CO2024014835A2 (es) Formulaciones de anticuerpos contra el receptor de interleucina 4 (il-4r)
MX2024013478A (es) Metodos para reducir la actividad de la lipasa
US8529939B2 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
EP4588938A3 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
CN102834091B (zh) 一种快速溶解药物组合物
JP6174585B2 (ja) 速溶性医薬組成物
JP5907945B2 (ja) 速溶解性医薬組成物
KR20230015351A (ko) 코로나바이러스 백신
Sou et al. Spray-dried influenza antigen with trehalose and leucine produces an aerosolizable powder vaccine formulation that induces strong systemic and mucosal immunity after pulmonary administration
US11160869B2 (en) Compositions, formulations and interleukin production and purification
KR20070111497A (ko) 약의 경점막 투여에 유용한 새로운 약학 조성물
MX2022008949A (es) Formulacion de anticuerpos estable.
JP2009521398A5 (cg-RX-API-DMAC7.html)
US8241886B2 (en) Formulations for preservation of rotavirus
DK1441704T3 (da) Orodispersibel tablet med höj homogenitet og fremgangsmåde til fremstilling heraf
SA521430229B1 (ar) Il-33 صيغ ثابتة تحتوي على أجسام مضادة لـ
CY1121233T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)
MX2023010059A (es) Metodos y composiciones para la administracion de particulas retrovirales.
AR129200A1 (es) Métodos para reducir la actividad lipasa
MX2022016218A (es) Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4.
NO20033451L (no) Medikamenter
AU2011224102B2 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
KR20190104322A (ko) 속붕해성 약학적 조성물
KR20180095817A (ko) 열적으로 안정한 로타바이러스 백신 제제 및 그의 사용 방법